Debt-to-EBITDA measures a company's ability to pay off its debt.
Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $817 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $35,705 Mil. Amgen's annualized EBITDA for the quarter that ended in Jun. 2022 was $10,748 Mil.
Amgen's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 3.40.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Amgen's Debt-to-EBITDA or its related term are showing as below:
AMGN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.37 Med: 2.79 Max: 4.24
Current: 3.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of Amgen was 4.24. The lowest was 2.37. And the median was 2.79.
AMGN's Debt-to-EBITDA is ranked worse than 67.18% of 649
companies
in the Drug Manufacturers industry
Industry Median: 1.57
vs AMGN: 3.01
Amgen Debt-to-EBITDA Historical Data
The historical data trend for Amgen's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Debt-to-EBITDA
2.75
2.63
2.37
2.54
2.95
Amgen Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Debt-to-EBITDA
4.84
2.85
2.51
3.28
3.40
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Debt-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amgen's Debt-to-EBITDA falls into.
Amgen Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Amgen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Amgen Debt-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Amgen's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
3.73(1.5%) Volume: 2,628,561 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:AMGN has been successfully added to your 
